Overview

Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer

Status:
Unknown status

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the rate of disease free survival (DFS) and distant disease free survival (DDFS) at 5 years in postmenopausal women with hormone receptor and lymph node positive breast cancer randomized between anastrozole/letrozole 5 years and anastrozole/letrozole 2-3 years switching to exemestane 3-2 years.

Phase:

Phase 3

Details

Lead Sponsor:

Fudan University

Treatments:

Anastrozole
Exemestane
Hormones
Letrozole